Click for best price
Hepatocellular Carcinoma Drugs Market Size, Share 2023
HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.
This report aims to provide a comprehensive presentation of the global market for Hepatocellular Carcinoma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocellular Carcinoma Drugs. This report contains market size and forecasts of Hepatocellular Carcinoma Drugs in global, including the following market information:
Global Hepatocellular Carcinoma Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Hepatocellular Carcinoma Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.
We surveyed the Hepatocellular Carcinoma Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hepatocellular Carcinoma Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Hepatocellular Carcinoma Drugs Market Segment Percentages, by Type, 2022 (%)
Brachytherapy
Chemotherapy
Local Ablation Therapy
Global Hepatocellular Carcinoma Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Hepatocellular Carcinoma Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Cancer Rehabilitation Centers
Global Hepatocellular Carcinoma Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Hepatocellular Carcinoma Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hepatocellular Carcinoma Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hepatocellular Carcinoma Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Eli Lilly
Johnson and Johnson
Pfizer
Bristol-Myers Squibb
Celgene
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck
Novartis
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hepatocellular Carcinoma Drugs, market overview.
Chapter 2: Global Hepatocellular Carcinoma Drugs market size in revenue.
Chapter 3: Detailed analysis of Hepatocellular Carcinoma Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hepatocellular Carcinoma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Hepatocellular Carcinoma Drugs Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
65 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hepatocellular Carcinoma Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hepatocellular Carcinoma Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hepatocellular Carcinoma Drugs Overall Market Size
2.1 Global Hepatocellular Carcinoma Drugs Market Size: 2022 VS 2029
2.2 Global Hepatocellular Carcinoma Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hepatocellular Carcinoma Drugs Players in Global Market
3.2 Top Global Hepatocellular Carcinoma Drugs Companies Ranked by Revenue
3.3 Global Hepatocellular Carcinoma Drugs Revenue by Companies
3.4 Top 3 and Top 5 Hepatocellular Carcinoma Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Hepatocellular Carcinoma Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hepatocellular Carcinoma Drugs Players in Global Market
3.6.1 List of Global Tier 1 Hepatocellular Carcinoma Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Hepatocellular Carcinoma Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Hepatocellular Carcinoma Drugs Market Size Markets, 2022 & 2029
4.1.2 Brachytherapy
4.1.3 Chemotherapy
4.1.4 Local Ablation Therapy
4.2 By Type - Global Hepatocellular Carcinoma Drugs Revenue & Forecasts
4.2.1 By Type - Global Hepatocellular Carcinoma Drugs Revenue, 2018-2023
4.2.2 By Type - Global Hepatocellular Carcinoma Drugs Revenue, 2024-2029
4.2.3 By Type - Global Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hepatocellular Carcinoma Drugs Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Cancer Rehabilitation Centers
5.2 By Application - Global Hepatocellular Carcinoma Drugs Revenue & Forecasts
5.2.1 By Application - Global Hepatocellular Carcinoma Drugs Revenue, 2018-2023
5.2.2 By Application - Global Hepatocellular Carcinoma Drugs Revenue, 2024-2029
5.2.3 By Application - Global Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Hepatocellular Carcinoma Drugs Market Size, 2022 & 2029
6.2 By Region - Global Hepatocellular Carcinoma Drugs Revenue & Forecasts
6.2.1 By Region - Global Hepatocellular Carcinoma Drugs Revenue, 2018-2023
6.2.2 By Region - Global Hepatocellular Carcinoma Drugs Revenue, 2024-2029
6.2.3 By Region - Global Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Hepatocellular Carcinoma Drugs Revenue, 2018-2029
6.3.2 US Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.3.3 Canada Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.3.4 Mexico Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Hepatocellular Carcinoma Drugs Revenue, 2018-2029
6.4.2 Germany Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.4.3 France Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.4.4 U.K. Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.4.5 Italy Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.4.6 Russia Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.4.8 Benelux Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Hepatocellular Carcinoma Drugs Revenue, 2018-2029
6.5.2 China Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.5.3 Japan Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.5.4 South Korea Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.5.6 India Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Hepatocellular Carcinoma Drugs Revenue, 2018-2029
6.6.2 Brazil Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.6.3 Argentina Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Hepatocellular Carcinoma Drugs Revenue, 2018-2029
6.7.2 Turkey Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.7.3 Israel Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Hepatocellular Carcinoma Drugs Market Size, 2018-2029
6.7.5 UAE Hepatocellular Carcinoma Drugs Market Size, 2018-2029
7 Hepatocellular Carcinoma Drugs Companies Profiles
7.1 Bayer
7.1.1 Bayer Company Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Hepatocellular Carcinoma Drugs Major Product Offerings
7.1.4 Bayer Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.1.5 Bayer Key News & Latest Developments
7.2 Eli Lilly
7.2.1 Eli Lilly Company Summary
7.2.2 Eli Lilly Business Overview
7.2.3 Eli Lilly Hepatocellular Carcinoma Drugs Major Product Offerings
7.2.4 Eli Lilly Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.2.5 Eli Lilly Key News & Latest Developments
7.3 Johnson and Johnson
7.3.1 Johnson and Johnson Company Summary
7.3.2 Johnson and Johnson Business Overview
7.3.3 Johnson and Johnson Hepatocellular Carcinoma Drugs Major Product Offerings
7.3.4 Johnson and Johnson Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.3.5 Johnson and Johnson Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Hepatocellular Carcinoma Drugs Major Product Offerings
7.4.4 Pfizer Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Major Product Offerings
7.5.4 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.5.5 Bristol-Myers Squibb Key News & Latest Developments
7.6 Celgene
7.6.1 Celgene Company Summary
7.6.2 Celgene Business Overview
7.6.3 Celgene Hepatocellular Carcinoma Drugs Major Product Offerings
7.6.4 Celgene Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.6.5 Celgene Key News & Latest Developments
7.7 F. Hoffmann-la Roche
7.7.1 F. Hoffmann-la Roche Company Summary
7.7.2 F. Hoffmann-la Roche Business Overview
7.7.3 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Major Product Offerings
7.7.4 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.7.5 F. Hoffmann-la Roche Key News & Latest Developments
7.8 Gilead
7.8.1 Gilead Company Summary
7.8.2 Gilead Business Overview
7.8.3 Gilead Hepatocellular Carcinoma Drugs Major Product Offerings
7.8.4 Gilead Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.8.5 Gilead Key News & Latest Developments
7.9 GlaxoSmithKline
7.9.1 GlaxoSmithKline Company Summary
7.9.2 GlaxoSmithKline Business Overview
7.9.3 GlaxoSmithKline Hepatocellular Carcinoma Drugs Major Product Offerings
7.9.4 GlaxoSmithKline Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.9.5 GlaxoSmithKline Key News & Latest Developments
7.10 Merck
7.10.1 Merck Company Summary
7.10.2 Merck Business Overview
7.10.3 Merck Hepatocellular Carcinoma Drugs Major Product Offerings
7.10.4 Merck Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.10.5 Merck Key News & Latest Developments
7.11 Novartis
7.11.1 Novartis Company Summary
7.11.2 Novartis Business Overview
7.11.3 Novartis Hepatocellular Carcinoma Drugs Major Product Offerings
7.11.4 Novartis Hepatocellular Carcinoma Drugs Revenue in Global Market (2018-2023)
7.11.5 Novartis Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Hepatocellular Carcinoma Drugs Market Opportunities & Trends in Global Market
Table 2. Hepatocellular Carcinoma Drugs Market Drivers in Global Market
Table 3. Hepatocellular Carcinoma Drugs Market Restraints in Global Market
Table 4. Key Players of Hepatocellular Carcinoma Drugs in Global Market
Table 5. Top Hepatocellular Carcinoma Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Hepatocellular Carcinoma Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Hepatocellular Carcinoma Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Hepatocellular Carcinoma Drugs Product Type
Table 9. List of Global Tier 1 Hepatocellular Carcinoma Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hepatocellular Carcinoma Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Hepatocellular Carcinoma Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Hepatocellular Carcinoma Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Hepatocellular Carcinoma Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Hepatocellular Carcinoma Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Hepatocellular Carcinoma Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Hepatocellular Carcinoma Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2024-2029
Table 30. Bayer Company Summary
Table 31. Bayer Hepatocellular Carcinoma Drugs Product Offerings
Table 32. Bayer Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Bayer Key News & Latest Developments
Table 34. Eli Lilly Company Summary
Table 35. Eli Lilly Hepatocellular Carcinoma Drugs Product Offerings
Table 36. Eli Lilly Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Eli Lilly Key News & Latest Developments
Table 38. Johnson and Johnson Company Summary
Table 39. Johnson and Johnson Hepatocellular Carcinoma Drugs Product Offerings
Table 40. Johnson and Johnson Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Johnson and Johnson Key News & Latest Developments
Table 42. Pfizer Company Summary
Table 43. Pfizer Hepatocellular Carcinoma Drugs Product Offerings
Table 44. Pfizer Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Pfizer Key News & Latest Developments
Table 46. Bristol-Myers Squibb Company Summary
Table 47. Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Product Offerings
Table 48. Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Bristol-Myers Squibb Key News & Latest Developments
Table 50. Celgene Company Summary
Table 51. Celgene Hepatocellular Carcinoma Drugs Product Offerings
Table 52. Celgene Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Celgene Key News & Latest Developments
Table 54. F. Hoffmann-la Roche Company Summary
Table 55. F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Product Offerings
Table 56. F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. F. Hoffmann-la Roche Key News & Latest Developments
Table 58. Gilead Company Summary
Table 59. Gilead Hepatocellular Carcinoma Drugs Product Offerings
Table 60. Gilead Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Gilead Key News & Latest Developments
Table 62. GlaxoSmithKline Company Summary
Table 63. GlaxoSmithKline Hepatocellular Carcinoma Drugs Product Offerings
Table 64. GlaxoSmithKline Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. GlaxoSmithKline Key News & Latest Developments
Table 66. Merck Company Summary
Table 67. Merck Hepatocellular Carcinoma Drugs Product Offerings
Table 68. Merck Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Merck Key News & Latest Developments
Table 70. Novartis Company Summary
Table 71. Novartis Hepatocellular Carcinoma Drugs Product Offerings
Table 72. Novartis Hepatocellular Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. Novartis Key News & Latest Developments
List of Figures
Figure 1. Hepatocellular Carcinoma Drugs Segment by Type in 2022
Figure 2. Hepatocellular Carcinoma Drugs Segment by Application in 2022
Figure 3. Global Hepatocellular Carcinoma Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Hepatocellular Carcinoma Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Hepatocellular Carcinoma Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hepatocellular Carcinoma Drugs Revenue in 2022
Figure 8. By Type - Global Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
Figure 16. US Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
Figure 28. China Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Hepatocellular Carcinoma Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Hepatocellular Carcinoma Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. Bayer Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Eli Lilly Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Johnson and Johnson Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Pfizer Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Celgene Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Gilead Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. GlaxoSmithKline Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Merck Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Novartis Hepatocellular Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
